Abbott Medical XIENCE Skypoint Everolimus Eluting Coronary Stent System

Indicated for improving coronary artery luminal diameter in the following: • Patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions • For restoring coronary flow in patients experiencing acute myocardial infarction who present within 12 hours of symptom onset • For the treatment of patients with concomitant diabetes, acute coronary syndrome, dual vessel lesions, lesions residing within small coronary vessels; lesions where treatment results in the jailing of side branches; for the treatment of elderly patients (age ≥ 65), and for treatment of both men and women • For treatment of patients with high bleeding risk under dual anti-platelet therapy as short as 28 days • For the treatment of patients presenting with in-stent restenosis in coronary artery lesions; chronic total occluded coronary artery lesions, coronary artery bifurcation lesions and • Left main coronary artery lesions for lengths up to 38mm